<unk>  (TCR-T) is a type of cancer immunotherapy. TCR-T therapies use heterodimers made of alpha and beta peptide chains to recognize MHC-presented polypeptide fragments molecules. Unlike CAR-T's cell surface antigens, TCR-T can recognize that larger set of intracellular antigen fragments. However, TCR-T cell therapy depends on MHC molecules, limiting its usefulness. Each T cell's TCR is specific to one antigen and sits on the T cell's surface. The affinity of human TCRs to tumor antigens is relatively low, which left them unable to recognize and kill tumor cells effectively. The modified T cell has much higher affinity, which enhances both recognition and affinity supporting the recognition of tumor cells. As of 2021, no TCR-T T cell therapies have been approved by regulatory authorities.
T cell receptor T cell therapy
Autologous immune enhancement therapy
Stem-cell therapy
T-cell vaccination
Active immunotherapy
Chemoimmunotherapy
Tumor antigen vaccine
Cancer vaccine targeting CD4+ T cells